CBOE GLOBAL MARKETS, INC. Tanzeel Akhtar 6/19/2019 2:43:49 PM
Merck & Co., Inc. (NYSE: MRK) is preparing for the departure of its CEO Kenneth Frazier and searching internally for a replacement, according to Bloomberg.
In May, Merck announced an agreement to acquire the clinical-stage biopharmaceutical company Peloton Therapeutics for $1.05 billion cash upfront and a further $1.15 billion if certain regulatory and sales milestones are reached.
On Wednesday, Merck & Co shares are trading up 0.19% at $84.66.
Related Links:
The Daily Biotech Pulse: Positive Readouts From Adamas And Ironwood, Sesen Bio To Offer Shares, Stoke Therapeutics Debut
Merck To Buy Clinical-Stage Biopharma Peloton Therapeutics For More Than $1B
Photo courtesy of Merck.
Attachments
- Original document
- Permalink
Disclaimer
CBOE Holdings Inc. published this content on 19 June 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 19 June 2019 20:23:03 UTC
